Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al

J Clin Oncol. 2018 Oct 20;36(30):3065-3066. doi: 10.1200/JCO.2018.79.3208. Epub 2018 Sep 6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Androstenes
  • Humans
  • Male
  • Prospective Studies
  • Prostatic Neoplasms, Castration-Resistant*

Substances

  • Androstenes
  • abiraterone